Document Detail

Low-intensity oral anticoagulation in sickle-cell disease reverses the prethrombotic state: promises for treatment?
MedLine Citation:
PMID:  7647016     Owner:  NLM     Status:  MEDLINE    
Increased plasma levels of prothrombin fragment 1 + 2 (F1 + 2) found in patients with sickle-cell disease reflect enhanced endogenous thrombin generation. We postulate that hypercoagulability contributes to vaso-occlusion. The intensity of acenocoumarol treatment required to reduce the F1 + 2 level to 50% of pretreatment level was investigated in seven patients with symptomatic sickle-cell anaemia during steady-state disease for a period of 2 months. All patients had increased levels of F1 + 2 compared with an age-matched control group. Normalization of the F1 + 2 was achieved at a median INR of 1.64 (range 1.18-2.2). It is concluded that low-intensity oral anticoagulation normalizes the hypercoagulability in sickle-cell disease.
H J Wolters; H ten Cate; L L Thomas; D P Brandjes; A van der Ende; Y van der Heiden; L W Statius van Eps
Related Documents :
1492006 - Potential warfarin-ciprofloxacin interaction in patients receiving long-term anticoagul...
10391426 - Outpatient self-management of warfarin therapy: a pilot study.
8239766 - Patients with antiphospholipid antibodies and venous thrombosis should receive long ter...
20053426 - Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation.
11133596 - A randomized, double-blinded comparison of intrathecal morphine, sufentanil and their c...
15358846 - Computer-aided detection performance in mammographic examination of masses: assessment.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  British journal of haematology     Volume:  90     ISSN:  0007-1048     ISO Abbreviation:  Br. J. Haematol.     Publication Date:  1995 Jul 
Date Detail:
Created Date:  1995-09-25     Completed Date:  1995-09-25     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0372544     Medline TA:  Br J Haematol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  715-7     Citation Subset:  IM    
Slotervaart Municipal Hospital, Department of Internal Medicine, Amsterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acenocoumarol / administration & dosage*
Administration, Oral
Hemoglobin SC Disease / blood,  drug therapy*
Peptide Fragments / metabolism
Protein Precursors / metabolism
Prothrombin / metabolism
Thrombin / metabolism*
Reg. No./Substance:
0/Peptide Fragments; 0/Protein Precursors; 152-72-7/Acenocoumarol; 72270-84-9/prothrombin fragment 1; 78768-79-3/prothrombin fragment 2; 9001-26-7/Prothrombin; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Growth inhibition of leukaemic cells carrying the t(3;21) by the AML1/EVI-1-specific antisense oligo...
Next Document:  Predicting the severity of haemolytic disease of the newborn: an assessment of the clinical usefulne...